Skip to main content

Dana-Farber Research News 07.01.2025

Welcome to Dana-Farber's Research News

View Archive Newsletters

July 1, 2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 through June 15.

If you are a Dana-Farber faculty member and you think your paper is missing from Research News, please let us know by emailing dfciresearchnews@dfci.harvard.edu.

Blood

An in Vivo Barcoded CRISPR-Cas9 Screen Identifies Ncoa4-Mediated Ferritinophagy as a Dependence in Tet2-Deficient Hematopoiesis

Loke J, Kim PG, Nguyen TTP, Boileau M, McConkey M, Miller AP, Shin W, Hergott CB, Ericsson M, Nordstrom A, Montero-Llopis P, Armstrong SA, Mancias JD, Ebert BL

TET2 is among the most commonly mutated genes in both clonal hematopoiesis and myeloid malignancies, thus, the ability to identify selective dependencies in TET2 deficient cells has broad translational significance. Here, we identify regulators of Tet2 knockout (KO) hematopoietic stem and progenitor cell (HSPC) expansion using an in vivo CRISPR-Cas9 KO screen, in which nucleotide barcoding enabled large-scale clonal tracing of Tet2 deficient HSPCs in a physiological setting. Our screen identified candidate genes, including Ncoa4, that are selectively required for Tet2 KO clonal outgrowth compared to wild-type (WT). Ncoa4 targets ferritin for lysosomal degradation (ferritinophagy), maintaining intracellular iron homeostasis by releasing labile iron (Fe2+) in response to cellular demands. In Tet2-deficient HSPCs, increased mitochondrial ATP production correlates with increased cellular iron requirements, and in turn, promotes Ncoa4-dependent ferritinophagy. Restricting iron availability reduces Tet2 KO stem cell numbers, revealing a dependency in TET2-mutated myeloid neoplasms.

 

Blood

TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?

Stahl M

Despite advances in the treatment paradigm of patients with acute myeloid leukemia (AML), TP53-mutated AML represents a molecular subgroup that has failed to improve, with an overall survival of ?6 months that is independent of age and fitness. Notably, there has been significant elucidation in understanding the biology of the disease and key advancements in the classification and prognostication of these patients. International collaborative efforts for novel clinical interventions are urgently needed to change the standard of care.

 

Cancer Discovery

Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements

Nakazawa S, Pecci F, Odintsov I, Gazgalis D, Gottlieb FH, Ricciuti B, Alessi JV, Di Federico A, Aldea M, Garbo E, Gandhi MM, Saini A, Feng WW, Jiang J, Baldacci S, Facchinetti F, Makarem M, Locquet MA, Haratani K, Haradon D, Che J, Sholl LM, Jänne PA, Awad MM

Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating the antitumor activity of MET inhibitors in MET rearrangement-positive cancers are limited. In this study, in a pan-cancer analysis of >46,000 solid tumors with comprehensive genomic profiling, we identified oncogenic MET rearrangements in ?0.04% of cancers. Preliminary analysis from a phase II clinical trial of the type I MET tyrosine kinase inhibitor (TKI) vebreltinib in MET fusion-positive solid tumors demonstrated an objective response rate of 50% and disease control rate of 79%, with antitumor activity seen in diverse cancer types, including lung adenocarcinoma and intrahepatic cholangiocarcinoma, among others. Similar to MET exon 14-altered lung cancer, secondary mutations in the kinase domain can confer resistance to MET TKIs in MET fusion-positive cancers. Overall, these data categorize MET rearrangements as actionable targets in solid tumors.

SIGNIFICANCE: MET rearrangement-positive cancers are not well-characterized, and optimal treatment strategies are yet to be defined. Through comprehensive genomic analysis, preclinical modeling, and preliminary results of a phase II clinical trial, we demonstrate that MET fusions are a unique molecular subtype of cancers targetable with vebreltinib, a TKI in development.

 

Cell Stem Cell

Intestinal Secretory Differentiation Reflects Niche-Driven Phenotypic and Epigenetic Plasticity of a Common Signal-Responsive Terminal Cell

Bhattacharya S, Tie G, Singh PNP, He R, Kraiczy J, Perlov Y, Shivdasani RA

Enterocytes and four classic secretory cell types derive from intestinal epithelial stem cells. Based on morphology, location, and canonical markers, goblet and Paneth cells are considered distinct secretory types. Here, we report high overlap in their transcripts and sites of accessible chromatin, in marked contrast to those of their enteroendocrine or tuft cell siblings. Mouse and human goblet and Paneth cells express extraordinary fractions of few antimicrobial genes, which reflect specific responses to local niches. Wnt signaling retains some ATOH1+ secretory cells in crypt bottoms, where the absence of BMP signaling potently induces Paneth features. Cells that migrate away from crypt bottoms encounter BMPs and thereby acquire goblet properties. These phenotypes and underlying accessible cis-elements interconvert in post-mitotic cells. Thus, goblet and Paneth properties represent alternative phenotypic manifestations of a common signal-responsive terminal cell type. These findings reveal exquisite niche-dependent cell plasticity and cis-regulatory dynamics in likely response to antimicrobial needs.

 

Journal of Clinical Oncology

Can Improving Adjuvant Endocrine Therapy Persistence Improve Survival Outcomes for Patients with Early-Stage Breast Cancer?

Tesch ME, Partridge AH

In the early 1990s, an Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis of adjuvant tamoxifen trials in patients with early breast cancer demonstrated significant reductions in the risk of death from breast cancer with tamoxifen in postmenopausal women. However, no clear survival advantage was seen in premenopausal women owing to little data in this subgroup, which, in part, led to tamoxifen routinely not being used in younger patients. An updated EBCTCG meta-analysis later established that 5 years of adjuvant tamoxifen substantially improved survival in both postmenopausal and premenopausal women, bringing into harsh focus the number of lives that could have been saved had the benefits of tamoxifen in younger patients been known sooner. Similarly, it was not until the SOFT/TEXT trials investigated adjuvant aromatase inhibitors (AI) in combination with ovarian function suppression (OFS) for premenopausal breast cancer that young patients became eligible, at last, for treatment with AI, over a decade after AIs had become the preferred adjuvant endocrine therapy (ET) for postmenopausal patients with hormone receptor (HR)–positive breast cancer, given their well-established superiority over tamoxifen. These examples underscore the need for dedicated studies in young adults with breast cancer, in whom the incidence of breast cancer has risen more sharply in recent years and whose survival rates remain lower, as compared with older adults.

 

Journal of Clinical Oncology

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Samur MK, Sperling AS, Raje NS, Ghobrial IM, Anderson KC, Munshi NC

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20% clonal fraction, and/or TP53 mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32); (3) monoallelic del(1p32) along with 1q+ or biallelic del(1p32); or (4) ?2 microglobulin ?5.5 mg/L with normal creatinine (<1.2 mg/dL).

 

JAMA

Why Good Palliative Care Clinicians Get Fired

Rosenberg AR, Rabinowitz E

Even the most seasoned palliative care clinician gets fired. In the past year, one of us was fired after asking whether a patient endorsing suicidal ideation had access to a gun; the patient requested not to see the palliative care team because we asked intrusive questions and documented the encounter. One of us was fired after supporting a family’s decision to discontinue life-sustaining therapies for their loved one with multisystem organ failure; the primary intensivist suggested palliative care overstepped in discussing options for which the family (and clinical teams) was not ready. And one of us was fired after sharing the impression that a patient with cancer was dying; the family suggested they preferred the oncologist’s version of a more hopeful future.

 

JAMA Oncology

Caring for Fasting Patients with Cancer During Ramadan

Mora J, Bakhtiar M, Saeed NA, Balboni TA

Ramadan is the ninth month of the Islamic lunar calendar and represents a holy time for Muslims worldwide to dedicate themselves to prayer, fasting, and community. During Ramadan, some observant Muslim patients with cancer may elect to fast. While some studies explore the impact of intentional caloric restriction on cancer therapy, the effect of repetitive daytime fasting for religious purposes has not been well characterized. Nevertheless, oncology clinicians should familiarize themselves with this cultural practice due to the potential clinical implications for patients.

 

JAMA Oncology

What Age Is the Best "FIT" for Colorectal Cancer Screening?

Jayakrishnan T, Ng K

Early-onset colorectal cancer (eoCRC), defined as colorectal cancer (CRC) diagnosed in individuals younger than 50 years, is one of the most rapidly increasing malignancies among young adults globally.1 The highest incidence rates of eoCRC have been reported in Australia, with an age-standardized rate (ASR) of 16.5 per 100?000 population (95% CI, 16.1-16.9), followed by New Zealand (ASR, 14.8; 95% CI, 14.0-15.6), the US (ASR, 14.8; 95% CI, 14.7-14.9), and South Korea (ASR, 14.3; 95% CI, 14.0-14.5). While the overall incidence of CRC in the US has declined by approximately 1.3% to 4.2% annually since the mid-1990s, the incidence of eoCRC has increased by about 2% per year during this timeframe. In parallel, CRC-related mortality among individuals younger than 50 years has also risen by approximately 1% per year between 2011 and 2020, with CRC now being the leading cause of cancer-related death in men aged 20 to 49 years in the US and the second leading cause in women of the same age group. The alarming rise of eoCRC prompted the US Preventive Services Task Force to lower the recommended starting age for CRC screening in average-risk individuals from age 50 to 45 years in 2021. However, most screening programs in other countries initiate screening at age 50 years. Furthermore, unlike the US, which largely relies on colonoscopy as the primary screening modality, most other countries rely on less resource-intensive, noninvasive stool-based tests such as the fecal immunochemical test (FIT) and fecal occult blood test. Thus, as the burden of eoCRC continues to grow around the world, there is an urgent need to better understand the effectiveness of these noninvasive tools in younger populations.

 

Nature Biotechnology

A CAR Enhancer Increases the Activity and Persistence of CAR T Cells

Rakhshandehroo T, Mantri SR, Moravej H, Louis BBV, Salehi Farid A, Munaretto L, Khan RMM, Wolff A, Farkash Z, Cong M, Kuhnast A, Nili A, Lee UJ, Allen HH, Berland L, Simkova E, Uslu SC, Tavakolpour S, Rowley JE, Codet E, Shahbazian H, Baral J, Pyrdol J, Jacobson CA, Nadeem O, Wucherpfennig KW, Rashidian M

Although chimeric antigen receptor (CAR) T cell therapies have demonstrated promising clinical outcomes, durable remissions remain limited. To extend the efficacy of CAR T cells, we develop a CAR enhancer (CAR-E), comprising a CAR T cell antigen fused to an immunomodulatory molecule. Here we demonstrate this strategy using B cell maturation antigen (BCMA) CAR T cells for the treatment of multiple myeloma, with a CAR-E consisting of the BCMA fused to a low-affinity interleukin 2 (IL-2). This selectively induces IL-2 signaling in CAR T cells upon antigen-CAR binding, enhancing T cell activation and antitumor activity while reducing IL-2-associated toxicities. We show that the BCMA CAR-E selectively binds CAR T cells and increases CAR T cell proliferation, clearance of tumor cells and development of memory CAR T cells. The memory cells retain the ability to re-expand upon restimulation, effectively controlling tumor growth upon rechallenge. Mechanistic studies reveal the involvement of both CAR and IL-2 receptor endodomains in the CAR-E mechanism of action. The CAR-E approach avoids the need for specific engineering and enables CAR T cell therapy with lower cell doses.

 

Nature Biotechnology

Systematic Identification of Minor Histocompatibility Antigens Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation

Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Stevens J, Kfuri-Rubens R, Shao Y, Kooshesh KA, Powell K, Ji H, Hernandez GM, Abelin J, Klaeger S, Forman C, Clauser KR, Sarkizova S, Braun DA, Penter L, Kim HT, Lane WJ, Oliveira G, Kean LS, Li S, Livak KJ, Carr SA, Keskin DB, Ho VT, Ritz J, Soiffer RJ, Neuberg D, Stewart C, Getz G, Wu CJ

T cell alloreactivity against minor histocompatibility antigens (mHAgs)-polymorphic peptides resulting from donor-recipient (D-R) disparity at sites of genetic polymorphisms-is at the core of the therapeutic effect of allogeneic hematopoietic cell transplantation (allo-HCT). Despite the crucial role of mHAgs in graft-versus-leukemia (GvL) and graft-versus-host disease (GvHD) reactions, it remains challenging to consistently link patient-specific mHAg repertoires to clinical outcomes. Here we devise an analytic framework to systematically identify mHAgs, including their detection on HLA class I ligandomes and functional verification of their immunogenicity. The method relies on the integration of polymorphism detection by whole-exome sequencing of germline DNA from D-R pairs with organ-specific transcriptional- and proteome-level expression. Application of this pipeline to 220 HLA-matched allo-HCT D-R pairs demonstrated that total and organ-specific mHAg load could independently predict the occurrence of acute GvHD and chronic pulmonary GvHD, respectively, and defined promising GvL targets, confirmed in a validation cohort of 58 D-R pairs, for the prevention or treatment of post-transplant disease recurrence.

 

Nature Genetics

Genomic Landscape of Multiple Myeloma and Its Precursor Conditions

Alberge JB, Dutta AK, Poletti A, Coorens THH, Lightbody ED, Toenges R, Loinaz X, Wallin S, Dunford A, Priebe O, Dagan J, Boehner CJ, Horowitz E, Su NK, Barr H, Hevenor L, Towle K, Beesam R, Beckwith JB, Perry J, Cordas Dos Santos DM, Bertamini L, Kübler K, Hess J, Sklavenitis-Pistofidis R, Stewart C, Getz G, Ghobrial IM

Reliable strategies to capture patients at risk of progression from precursor stages of multiple myeloma (MM) to overt disease are still missing. We assembled a comprehensive collection of MM genomic data comprising 1,030 patients (218 with precursor conditions) that we used to identify recurrent coding and non-coding candidate drivers as well as significant hotspots of structural variation. We used those drivers to define and validate a simple 'MM-like' score, which we could use to place patients' tumors on a gradual axis of progression toward active disease. Our MM precursor genomic map provides insights into the time of initiation and cell-of-origin of the disease, order of acquisition of genomic alterations and mutational processes found across the stages of transformation. Taken together, we highlight here the potential of genome sequencing to better inform risk assessment and monitoring of MM precursor conditions.

 

Nature Genetics

KDM4C Inhibition Blocks Tumor Growth in Basal Breast Cancer by Promoting Cathepsin L-Mediated Histone H3 Cleavage

Li Z, Peluffo G, Stevens LE, Qiu X, Seehawer M, Tawawalla A, Huang XY, Egri SB, Raval S, McFadden M, Kingston NL, Nishida J, Evans KE, Seo JH, Clement K, Temko D, Ekram M, Li R, Rees MG, Ronan MM, Roth JA, SMichor F, Meissner A, Freedman ML, Jaffe JD, Papanastasiou M, Long HW, Polyak K

Basal breast cancer is a subtype with a poor prognosis in need of more effective therapeutic approaches. Here we describe a unique role for the KDM4C histone lysine demethylase in KDM4C-amplified basal breast cancers, where KDM4C inhibition reshapes chromatin and transcriptomic landscapes without substantial alterations of its canonical substrates, trimethylated histone H3 lysine 9 (H3K9me3) and lysine 36 (H3K36me3). Rather, KDM4C loss causes proteolytic cleavage of histone H3 mediated by cathepsin L (CTSL), resulting in decreased glutamate-cysteine ligase expression and increased reactive oxygen species. CTSL is recruited to the chromatin by the grainyhead-like 2 (GRHL2) transcription factor that is methylated at lysine 453 following KDM4C inhibition, triggering CTSL histone clipping activity. Deletion of CTSL rescued KDM4-loss-mediated tumor suppression. Our study reveals a function for KDM4C that connects cellular redox regulation and chromatin remodeling.

 

New England Journal of Medicine

Menopausal Symptom Management in Breast Cancer Survivors - A Promising New Option

Among women with a history of early breast cancer treated with endocrine therapy (tamoxifen or aromatase inhibitors), vasomotor symptoms are common, occurring in up to 90% of this population, and often severe. These symptoms are attributable to mainstay treatments used to reduce disease recurrence and improve survival. Two such treatments are chemotherapy, which causes temporary or permanent ovarian suppression and is associated with precipitously low levels of estradiol in premenopausal women, and endocrine therapy, which is used to decrease or block estrogen in breast cancer survivors of all ages. Menopausal symptoms not only affect quality of life among survivors of breast cancer but also may have indirect adverse effects on disease-free and overall survival, especially if the symptoms lead to nonadherence to risk-reducing endocrine therapy. In a large cross-sectional study involving breast cancer survivors, half the participants reported nonadherence to endocrine therapy; nonadherence was significantly more likely among participants reporting more-severe vasomotor symptoms than those with less-severe symptoms, which suggests that improved symptom management is a vital issue in breast cancer care.

 

New England Journal of Medicine

The Fetal-to-Adult Hemoglobin Switch - Mechanism and Therapy

Orkin SH

The evolution of biomedical science can be appreciated through studies of hemoglobin, the oxygen-carrying protein in red cells. Before molecular cloning, the geneticist Arno Motulsky noted, “Many fundamental concepts have become clarified by investigations on human hemoglobins.” Half a century into the recombinant-DNA era, these words are even more apt. From gene cloning to editing, hemoglobin-related research has embraced emerging technologies and uncovered general principles. The accessibility of red cells for study, their extraordinary specialization for hemoglobin production, and the global burden of the major hemoglobin disorders, ?-thalassemia and sickle cell disease, sustain interest in the field.

 

ACS Chemical Biology

High-Throughput Screening Tool to Identify Small Molecule Inhibitors of Telomerase

Aquilanti E, Barkho S, Bozinov V, Kageler L, Garrity-Janger M, Mesleh MF, Horner S, Ranaghan MJ, Meyerson M

 

American Journal of Hematology

Poor Engraftment After Posttransplant Cyclophosphamide Graft-Versus-Host DISEASE Prophylaxis in Patients with Myelofibrosis

Kim HT, Liney DJ, Rizza K, Cutler CS, Koreth J, Nikiforow S, Shapiro RM, Kelkar AH, Gooptu M, Romee R, Wu CJ, Antin JH, Ritz J, Soiffer RJ, Ho VT

 

American Society of Clinical Oncology Educational Book

Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing

Corti C, Tolaney SM

 

American Society of Clinical Oncology Educational Book

Precursor Hematologic Conditions: Diagnosis, Risk Stratification, Clinical Implications, and Management

Liu Y, Nadeem O

 

Annals of Surgical Oncology

Gait Speed as a Measure of Frailty and Outcomes After Lung Resection

Singh A, Xie Y, Mazzola E, Wang S, McAllister M, Pezeshkian F, Frain LN, Wilder FG, Steimer D, Jaklitsch MT, DuMontier C

 

Annals of Surgical Oncology

Impact of the American Society of Breast Surgeons' Guidelines on Genetic Testing and Contralateral Prophylactic Mastectomy Rates

Weiss A, Rosito MS, Braun D, Barton B, McGrath M, Stokes S, Laws A, Warren L, Morganti S, Lynce F, Bychkovsky B, Rana HQ, Davis D, Stopfer J, Garber JE, King TA

 

Blood Advances

Characteristics and Outcomes of Patients with Double Refractory and Double Exposed Chronic Lymphocytic Leukemia

Yoon JT, Zhou Y, Mikhaleva M, Choi DS, Fernandes SM, Armand P, Bessnow AC, Crombie JL, Fisher DC, Jacobsen ED, Jacobson CA, Kim AI, LaCasce AS, Merryman RW, Odejide OO, Parry EM, Qualls DA, Ryan CE, Sekar A, Soumerai JD, Arnason J, Tyekucheva S, Davids MS, Brown JR, Ahn IE

 

Blood Advances

Prospective Study of Immunogenicity to SARS-CoV-2 Booster Vaccines in Multiple Myeloma and Waldenström Macroglobulinemia

Branagan AR, Mo CC, Lei MM, Gustine J, Yee AJ, O'Donnell E, Castillo JJ, Nadeem O, Flynn C, Bernstein Z, Nakamoto-Matsubara R, Meid KE, Verma R, Hunter ZR, Guerrera ML, Alter G, Burke JN, Harrington CC, Agyemang EA, Gammon MT, Lively KJ, Packer L, Horick N, Laubach JP, Mitsiades CS, Munshi NC, Anderson KC, Treon SP, Richardson PG, Raje NS, Sarosiek S

 

British Journal of Haematology

Development and Characterization of the Novel MYD88 Mutated, 6q Deleted BCWM.2 Cell Line for Waldenström Macroglobulinaemia

Liu S, Liu X, Yusuf CFB, Kofides A, Soroko KM, Penailillo J, Canning AG, Cao Y, Yang G, Xu L, Tsakmaklis N, Sun H, Guijosa A, Guerrera ML, Patterson CJ, Carrasco RD, Gokhale PC, Sarosiek SR, Castillo JJ, Hatcher JM, Hunter ZR, Treon SP

 

British Journal of Haematology

Forecasting Optimal Treatments in Relapsed/Refractory Mature T- and NK-Cell Lymphomas: A Global PETAL Consortium Study

Sorial MN, Lei MM, MacVicar CT, Freydman J, Malespini J, Aniagboso KN, McCabe SM, Singh S, Iwasaki M, Eche-Ugwu IJ, Gabler J, Fernandez Turizo MJ, Garg A, Disciullo A, Chopra K, Ford J, Lenart A, Nwodo E, Barnes J, Koh MJ, Merrill M, Jacobsen E, Kariya KM, Bhanushali F, Meharwal A, Mistry D, Kosovsky M, Jain S

 

Breast Cancer Research and Treatment

Breast Imaging Recommendations for Young Females (age <?40 years) with ??20% Lifetime Breast Cancer Risk: Practice Patterns at a Specialized Clinic

Wehbe A, Katlin F, Sharma E, Hans M, Graichen MK, Bychkovsky BL, Scheib R, Garber JE, Pace LE, King TA, Laws A

 

Cell Reports Medicine

Cell States and Neighborhoods in Distinct Clinical Stages of Primary and Metastatic Esophageal Adenocarcinoma

Yates J, Mathey-Andrews C, Park J, Garza A, Gagné A, Hoffman S, Bi K, Titchen B, Remland J, Carnes M, Shannon E, Camp S, Balamurali S, Cavale SK, Li Z, Raghawan AK, Boland G, Aguirre AJ, Sethi NS, Van Allen EM

 

Cell Reports Medicine

Combined Inhibition of KAT6A/B and Menin Reverses Estrogen Receptor-Driven Gene Expression Programs in Breast Cancer

Olsen SN, Anderson B, Hatton C, Wen Y, Bourgeois W, Haarer EL, Brown M, Jeselsohn R, Armstrong SA

 
 
 

Clinical Cancer Research

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Pecci F, Alden SL, Ricciuti B, Alessi JV, Wang X, Jeng M, Vaz VR, Barrichello A, Lamberti G, Di Federico A, Santo V, Rossato de Almeida G, Gandhi M, Nishino M, Johnson BE, Awad MM

 

Clinical Breast Cancer

Factors Associated with Short- and Long-Term Survival in Metastatic HER2-Positive Breast Cancer

Leone JP, Moges R, Parsons HA, Hassett MJ, Lin NU

 
 
 

Clinical Genitourinary Cancer

CDK4/6 Inhibition with Abemaciclib in Patients with Previously Treated Advanced Renal Cell Carcinoma

McGregor BA, Xie W, Berg SA, Xu W, Viswanathan SR, McDermott D, Signoretti S, Kaelin WG Jr, Choueiri TK

 

Clinical Lung Cancer

Association of Sarcopenia with Toxicity and Survival in Patients with Lung Cancer, a Multi-Institutional Study with External Dataset Validation

Saraf A, He J, Shin KY, Weiss J, Awad MM, Gainor J, Kann BH, Christiani DC, Aerts HJWL, Mak RH

 

Clinical Lung Cancer

Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older with Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (?50%) Patients

Barrichello APC, Ricciuti B, Wang X, Lotter W, Lindsay J, Santo V, Sharma B, Felt K, Pfaff K, Lamberti G, Pecci F, Federico AD, Makarem M, Gandhi MM, Nguyen T, Haradon D, Vaz VR, Johnson BE, Rodig SJ, Awad MM, Alessi JV

 

Current Treatment Options in Oncology

Epithelioid Hemangioendothelioma: Treatment Landscape and Innovations for an Ultra-Rare Sarcoma

Pimenta EM, Goyal A, Farber ON, Lilley E, Shyn PB, Wang J, Wagner MJ

 

European Journal of Haematology

Outcomes of Melflufen Treatment in Patients with Relapsed/Refractory Multiple Myeloma

Hossain S, Mo C, Patches S, Leblebjian H, Goodrich K, Regan E, O'Neill K, Noonan K, Richardson PG, Laubach J

 

European Urology

Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer

Ravi P, Kwak L, Rastogi S, Xie W, Abdelnaser A, Einstein DJ, Chang P, Wagner AA, Kibel AS, Taplin ME

 
 

European Urology Oncology

Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer

Ravi P, Zhong C, Xie W, Kelly E, Whelpley B, Kuczmarski K, Beltran H, Kilbridge KL, King MT, McGregor BA, Morgans AK, Pomerantz M, Taplin ME, Tewari AK, Viswanathan SR, Wei XX, Anh Huynh M, Choudhury AD

 

Gynecologic Oncology

A Phase I Clinical Trial of Radiation Therapy, Durvalumab and Tremelimumab in Recurrent Gynecologic Cancer

Fitzgerald KJ, Konstantinopoulos P, Matulonis U, Liu J, Horowitz N, Lee E, Kolin DL, Lee L, King M

 
 

Health Communication

The Relationship Between News Coverage of COVID-19 Misinformation and Online Search Behavior

Douglas-Durham E, Emmons KM, Viswanath K

 
 

Hematology Oncology

Diagnosis and Management of Waldenstrom's Macroglobulinemia

Treon SP, Sarosiek S, Castillo JJ

 

Hematology/Oncology Clinics of North America

Histiocytic Disorders in Pediatric and Adult Patients

Berliner N, Degar BA

 

Hematology/Oncology Clinics of North America

Clinical Characteristics and Treatment of Histiocytic Disorders in Children

Degar BA, Huang JT, Bledsoe J

 
 

International Journal of Radiation Oncology, Biology, Physics

The Benefit of Short-Term Androgen Deprivation Therapy with Radiation Therapy for Intermediate-Risk Prostate Cancer

D'Amico AV, Nguyen PL

 

Journal of Geriatric Oncology

Patterns of Presentation, Treatment, and Survival Among Older Adults with Metastatic Breast Cancer: Results from a Large Prospective Registry

Newman AB, Martin AR, Hughes ME, Higgins A, Kirkner GJ, Files J, Skeffington M, Moore M, Strauss S, Kuhnly N, Crowley L, Tolaney SM, Lin NU, Freedman RA

 

Journal of Geriatric Oncology

Preliminary Experience Supporting Older Adults with Breast Cancer: Successes, Challenges, and Next Steps for a Program Embedded in a Breast Oncology Center

Ruderman K, Simo S, McGrath B, Snow C, Rigby K, Arnaout A, Hshieh TT, Minami C, Freedman RA

 

Journal of Thoracic Oncology

Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association with the Outcomes of Immunotherapy with or without Chemotherapy in Nonsquamous NSCLC

Gandhi MM, Moore CG, Ricciuti B, Alessi JV, Williams J, Lamberti G, Pecci F, Di Federico A, Makarem M, Johnson BE, Nishino M, Sholl LM

 

JCO Oncology Practice

Beyond Opioids: A Multidisciplinary Approach to Cancer Pain Management

Azizoddin DR, Enzinger AC

 
 

JCO Precision Oncology

Efficacy and Safety of Tarlatamab in a Patient with Advanced Delta-Like Ligand 3-Positive Large Cell Neuroendocrine Lung Carcinoma and Untreated Brain Metastases: A Case Report

Gariazzo E, Laaksonen S, Canty S, De Almeida GR, Odintsov I, Santo V, Garbo E, Pecci F, Aldea M, Oser MG, Sholl L, Sands JM, Ricciuti B

 

JCO Precision Oncology

Incidental Diffuse Midline Glioma, H3 K27-Altered of the Pons Without Significant Coalterations

Yeo KK, Power P, Lidov H, Rosenberg T, Warren KE, Smith ER, Haas-Kogan D, Bandopadhayay P

 

Lancet Regional Health Europe

Enhancing Existing Tumour Biobanks in European Prospective Cohort Studies

Ugai T, Mucci LA, Ogino S

 

Nature Chemistry

Leveraging Relaxation-Optimized (1)H-(13)C(F) Correlations in 4-(19)F-Phenylalanine as Atomic Beacons for Probing Structure and Dynamics of Large Proteins

Boeszoermenyi A, Schindler S, Valadares V, Padmanabha Das KM, Dubey A, Viennet T, Ficarro S, Marto J, Geffken EA, Dhe-Paganon S, Seo HS, Arthanari H

 

Nature Review Immunology

CD45-PET Imaging Gives a Panoramic View of in Vivo Immune Activity

Djafari Rouhani S, Rashidian M

 
 
 
 
 
 

Prostate

Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience

Losee M, Kavanaugh M, Liu M, Borges N, Haberman V, Ritzer J, Wolanski A, Bhimaniya S, Choudhury AD, Hyun H, Stoltenberg H, Kilbridge KL, Morgans A, Pomerantz M, Robertson M, Sakellis C, Shah H, Taplin ME, Wei XX, Ng T, Ravi P, Jacene H

 
 

Radiotherapy and Oncology

Evaluating the Prognostic Significance of Artificial Intelligence-Delineated Gross Tumor Volume and Prostate Volume Measurements for Prostate Radiotherapy

Adleman J, McLaughlin PY, Tsui JMG, Buzurovic I, Harris T, Hudson J, Urribarri J, Cail DW, Nguyen PL, Orio PF, Lee LK, King MT

 
 
 

Transplantation and Cellular Therapy

A Structured Peer Support Intervention for Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation: Peer Support Interventionists' Perspectives

Guo M, Keane EP, Mate-Kole MN, Boardman AC, Larizza IS, Song MT, Schaefer DA, Cutler C, El-Jawahri A, Amonoo HL

 
 

Trends in Cancer

Mixing It Up: Boosting Responses with Immunotherapy Combinations

Komatsuda H, Sim ES, Uppaluri R